Full-Time

Research Associate

Biobanking

Parallel Biosystems

Parallel Biosystems

11-50 employees

AI-assisted immune organoid drug discovery platform

Compensation Overview

$70k - $85k/yr

San Francisco, CA, USA

In Person

Occasional weekend or off-hours work may be required for time-sensitive clinical samples.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
OSHA
HIPAA

Get referred to Parallel Biosystems

See people who can refer or advise you

Requirements
  • A Bachelor of Science or Master of Science degree in Biology, Immunology, Cell Biology, Biotechnology, or a related discipline.
  • At least 1 year of hands-on experience with human primary cell or tissue processing in an academic or industry laboratory.
  • Strong aseptic technique and routine experience with mammalian cell or tissue culture.
  • Experience using Laboratory Information Management Systems (LIMS) and/or Electronic Laboratory Notebooks (ELN) for structured sample and data tracking.
  • Ability to pass respirator fit testing and comply with personal protective equipment requirements under OSHA 29 CFR 1910.134, including maintaining facial hair compliant with a proper respirator seal.
  • Willingness to work onsite daily in San Francisco, with occasional weekend or off-hours work to process time-sensitive clinical samples.
  • Ability to work independently at the bench while communicating clearly with colleagues and clinical partners.
  • Ability to manage a large and evolving biological inventory in an organized and detail-oriented manner.
Responsibilities
  • Maintain rigorous, real-time chain-of-custody records for all samples, derivatives, and associated donor metadata in LIMS/ELN systems, ensuring the link between specimen and donor is never broken.
  • Receive, log, and process human biological samples, including whole blood, buffy coats, and lymphoid tissues, following established biosafety and ethical guidelines.
  • Isolate primary immune cells and other relevant cell types using density gradient centrifugation, magnetic separation, and related methods.
  • Perform routine tissue and cell culture, including plating, media changes, and monitoring of culture quality.
  • Execute and optimize cryopreservation and thawing protocols to maintain cell viability and function.
  • Maintain an organized, fit-for-purpose biobanking workspace, including freezers, liquid nitrogen storage, and tissue culture facilities.
  • Monitor and manage inventory of samples, reagents, and consumables, and coordinate ordering and restocking as needed.
  • Contribute to the development, documentation, and continuous improvement of standard operating procedures for sample receipt, processing, storage, and retrieval.
  • Support equipment maintenance and calibration for biosafety cabinets, centrifuges, and freezers, and proactively flag issues.
  • Ensure all incoming human tissue is accompanied by complete donor consent documentation and maintain awareness of applicable IRB protocols, HIPAA requirements, and material transfer agreements governing sample use and storage.
  • Perform basic quality control on incoming and banked samples, including cell counts, viability assays, and simple flow cytometry panels where applicable.
  • Coordinate the timing and logistics of clinical sample shipments, ensuring cold-chain integrity and proper documentation, including consent forms and material transfer agreements.
  • Work closely with discovery and platform teams to provide appropriately prepared samples for organoid culture and downstream assays.
  • Help troubleshoot sample- or workflow-related issues and propose practical improvements to enhance throughput and consistency.
Desired Qualifications
  • Familiarity with basic immunological or cell-based assays, such as viability staining, flow cytometry, and enzyme-linked immunosorbent assay (ELISA).

Parallel Biosystems provides a drug discovery platform that uses immune organoids, artificial intelligence (AI), and robotics to model human diseases and develop immunotherapies. It offers services to pharmaceutical companies, biotech firms, and research institutions, charging service fees, licensing, and milestone payments. The platform works by growing miniaturized human immune organoids in the lab, applying AI to analyze results and guide experiments, and using robotics to automate workflows, enabling faster, cheaper, and more accurate drug discovery than traditional methods. What sets Parallel Biosystems apart is its combination of human-relevant organoid models with AI analytics and automated lab systems, aiming to produce therapies that work across diverse populations. The company’s goal is to accelerate the development of safer and more effective drugs, speeding therapies from research to patients and expanding options for cancer, autoimmune, and age-related diseases.

Company Size

11-50

Company Stage

Series A

Total Funding

$25.4M

Headquarters

Cambridge, Massachusetts

Founded

2020

Get referred to Parallel Biosystems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 brought $21 million Series A backing from AIX Ventures, Benioff, and Dean.
  • Three Fortune 500 pharma partners are already testing over 50 drugs on-platform.
  • FDA's March 2026 NAMs draft guidance strengthens demand for human-relevant preclinical testing.

What critics are saying

  • Centivax is the clearest validation; losing that program would cripple commercial credibility by 2027.
  • FDA's NAMs push invites faster-following competitors like organoid and chip vendors into Parallel Bio's niche.
  • If pharma partners stop testing 50 drugs, Parallel Bio becomes a research curiosity, not a company.

What makes Parallel Biosystems unique

  • Parallel Bio combines immune organoids, AI, and robotics for human-first drug discovery.
  • June 2026 Bay Area headquarters consolidation tightly links computational and biological teams.
  • Its platform reports 87% concordance with clinical patient data, versus animals' 3%.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

13%

2 year growth

8%
HealthTech HotSpot
Jun 16th, 2026
Parallel Bio establishes San Francisco Bay Area as U.S. Headquarters, appoints five industry leaders to advisory board.

Parallel Bio establishes San Francisco Bay Area as U.S. Headquarters, appoints five industry leaders to advisory board. * Parallel Bio returns to Bay Area roots, bringing computational and biological operations under one roof * New advisors strengthen leadership in immunology, AI, drug development and cybersecurity SAN FRANCISCO-(BUSINESS WIRE)-Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it is centering U.S. operations at its San Francisco Bay Area headquarters in Brisbane, CA, bringing computational and biological functions together in one location. The move builds on Parallel Bio's Bay Area foundation, as co-founders Robert DiFazio and Juliana Hilliard founded the company in San Francisco in 2021. At the time, DiFazio worked at Stanford University, directing an interdisciplinary institute of over 150 faculty studying human immunology, and Hilliard worked at Herophilus (formerly known as System1), adapting brain organoid technology for high-throughput drug discovery. The company is backed by Bay Area investors including AIX Ventures, which led Parallel Bio's $21 million Series A round; Marc Benioff, founder and CEO of Salesforce; Jeff Dean, head of Google DeepMind; Y Combinator; and other biotech and deeptech funds. Parallel Bio also announced five new advisors as the company scales its platform and partnerships across multiple therapeutic areas: * Shane Crotty, Professor and Chief Scientific Officer at one of the world's leading institutes of human immunology * Ron Philip, former CEO of Orbital Therapeutics and Spark Therapeutics * Andre Esteva, CEO and co-founder of ArteraAI * Rick Bright, PhD, CEO of Bright Global Health and former Director of BARDA * Jason Kichen, Chief Information Security Officer of Fluidstack and adjunct faculty at the University of California, Berkeley. "For decades, the pharmaceutical industry has sought better ways to evaluate therapies in human biology before advancing into clinical studies. Parallel Bio is taking an important step toward addressing that challenge," said Philip. "I joined the advisory board because I believe their platform has the potential to meaningfully improve how new medicines are developed." These advisors bring deep experience across the company's core focus areas including human immunology, drug development, AI for medicine, and data infrastructure, positioning Parallel Bio to lead the transformation of drug development as the industry moves beyond animal testing. "We're fortunate to add these five exceptional advisors whose expertise will be invaluable as we scale our platform and partnerships," said DiFazio. "Likewise, bringing our team together in the Bay Area allows us to move faster and integrate our computational and biology work more tightly." With the move, Parallel Bio is actively recruiting scientific and engineering talent across the Bay Area. The company currently works with numerous pharmaceutical partners, including three Fortune 500 companies, who are testing more than 50 drugs and immunotherapies using Parallel Bio's organoid-based immune system modeling platform. "The Bay Area has always been our home, and this consolidation positions us to build on that foundation," said Hilliard. "We're excited to grow our team here and continue advancing human-first drug discovery with support from some of the world's leading experts in immunology, AI, and biotech." About Parallel Bio Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. The company generates data using groundbreaking biological and computational tools that track real clinical outcomes, enabling earlier, more reliable decisions about disease biology and drug discovery. The platform overcomes the core limitations of traditional animal testing, which almost always fails to predict how drugs will behave in people. Parallel Bio is building its own drug discovery pipeline in cancer and autoimmune disease while collaborating with pharmaceutical companies to evaluate therapies directly in human systems before costly and risky clinical trials. Founded in 2021 by two scientists with deep expertise in cutting-edge human models, Parallel Bio is backed by leading investors in AI and biotech, including AIX Ventures, Marc Benioff, and Jeff Dean. Learn more at parallel.bio.

Business Wire
Jun 16th, 2026
Parallel Bio consolidates US ops in San Francisco, adds five advisors including ex-Spark CEO

Parallel Bio, a biotech company pioneering human-first drug discovery, has established its US headquarters in Brisbane, California, consolidating computational and biological operations in the San Francisco Bay Area. The company was founded in San Francisco in 2021 by Robert DiFazio and Juliana Hilliard. The move accompanies the appointment of five industry leaders to its advisory board, including Shane Crotty, Ron Philip, Andre Esteva, Rick Bright and Jason Kichen. These advisors bring expertise across human immunology, drug development, AI for medicine and data infrastructure. Parallel Bio is backed by Bay Area investors including AIX Ventures, which led its $21 million Series A round, alongside Marc Benioff and Jeff Dean. The company currently works with pharmaceutical partners, including three Fortune 500 companies, testing over 50 drugs using its organoid-based immune system modelling platform.

Silverwood Partners
Jun 18th, 2025
Healthcare Private Placement and M&A Transactions Review Week Ending June 15, 2025

iView Therapeutics: The company raised $9.2 million of Series A venture funding in a deal led by Chongqing Dian Petrochemical Medical Fund Management on February 24, 2025.

Endpoints News
Jun 11th, 2025
Parallel Bio raises $21M for lymph node tech

Parallel Bio, a startup that has developed a method to grow miniature human lymph nodes in a dish, has secured $21 million in Series A funding.

Endpoints News
Jun 11th, 2025
Exclusive: Organoid startup raises $21M to test drugs and vaccines in human lymph nodes-in-a-dish

Parallel Bio, a startup that figured out how to grow miniature human lymph nodes in a dish, has raised $21 million in Series A funding...